Cancer drug combo shows promise for Hard-to-Treat bowel cancer
Disease control
Terminated
This study tested a combination of two drugs (atezolizumab and bevacizumab) in 46 people with advanced colorectal cancer that had stopped responding to chemotherapy and had a specific genetic marker called MSI-like. The goal was to see if the combination could shrink tumors. The …
Phase: PHASE2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated May 17, 2026 04:01 UTC